"Sulfones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013450
|
| MeSH Number(s) |
D02.886.590
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfones".
Below are MeSH descriptors whose meaning is more specific than "Sulfones".
This graph shows the total number of publications written about "Sulfones" by people in this website by year, and whether "Sulfones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 4 | 4 |
| 2006 | 1 | 5 | 6 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 5 | 2 | 7 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 3 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfones" by people in Profiles.
-
Development of Rofecoxib-Based Fluorescent Probes and Investigations on Their Solvatochromism, AIE Activity, Mechanochromism, and COX-2-Targeted Bioimaging. Anal Chem. 2021 09 07; 93(35):11991-12000.
-
Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer. 2021 08; 45(4):100768.
-
One-Step Transformation from Rofecoxib to a COX-2 NIR Probe for Human Cancer Tissue/Organoid Targeted Bioimaging. ACS Appl Bio Mater. 2021 03 15; 4(3):2723-2731.
-
Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker. Hypertens Res. 2020 11; 43(11):1204-1213.
-
Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice. J Am Heart Assoc. 2020 04 07; 9(7):e014044.
-
Rofecoxib and Clinically Significant Gastrointestinal Events: Response. Am J Med Sci. 2019 09; 358(3):e9-e10.
-
Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018 11 13; 138(20):2227-2242.
-
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast. J Ocul Pharmacol Ther. 2018 09; 34(7):543-549.
-
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15; 22(22):5527-5538.
-
Neuronal Rap1 Regulates Energy Balance, Glucose Homeostasis, and Leptin Actions. Cell Rep. 2016 09 13; 16(11):3003-3015.